SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Autologous, CAR-T, TCR

February 02, 2024

2seventy bio to Focus Exclusively on Abecma; Sells Pipeline to Regeneron; Afami-Cel BLA Granted Priority Review

Here is a brief preview of this blast: On Tuesday, January 30, 2seventy bio announced (press release) a new strategic path focusing exclusively on the commercialization and development of Abecma (BCMA CAR-T). In connection with this, and as shared (press release) by Regeneron, the company has entered into an asset purchase agreement with Regeneron to sell its oncology and autoimmune R&D programs, clinical manufacturing capabilities, and related platform technologies.